EUVIMEDEUVIMED entdecken
Crossref

Reproducibility crisis. Impact on uncontrolled release of nutraceutical preparations

Mariano Bizzarri, Noemi Monti

Organisms. Journal of Biological Sciences · 16.07.2019 · 3 (1) · 9-10

DOI: 10.13133/2532-5876_5.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organisms. Journal of Biological Sciences, erschienen am 16.07.2019. Verfasst von Mariano Bizzarri und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decade, natural integrative treatments of Polycystic Ovary Syndrome (PCOS) – a complex ovarian syndrome characterized by anovulation/androgenism/cystic ovaries – gained momentum, given that a plethora of nutraceuticals flooded into the market. Namely, two inositol isomers - myo-inositol (myo-Ins) and D-chiroinositol (D-Chiro-Ins) have been proven to be effective in PCOS treatment, by improving insulin resistance, serum androgen levels and many features of the metabolic syndrome. However, DCI alone, mostly when it is administered at high dosage, negatively affects oocyte quality. On the contrary, the association myo-Ins/DChiro-Ins in a combination reproducing the plasma physiological ratio (40:1) – as claimed by a Consensus Conference (Bevilacqua et al., 2015) and confirmed by a recent clinical pilot study (Nordio, 2019) - represents, up to now, the most promising alternative in achieving better clinical results, by counteracting PCOS at both systemic and ovary level. Honestly, we still lacking a compelling clinical vindication of that assumption, the outstanding experimental results performed in animals notwithstanding (Bevilacqua et al., 2019). However, data gathered suggest that the two inositol should be administered according to a physiological ratio, which would mirror the concentrations found in the blood (Bizzarri et al., 2016), or in the ovarian follicle (Chiu et al., 2002). However, only few, pivotal studies based on these correct physiological premises have been performed so far. It is staggering. As a result, a good opportunity – treatment of a complex syndrome through natural and safe compounds – risks to be wasted.

Schlagwörter

replication crisisnutraceuticalspolycystic ovary syndromemyo-inositolD-chiro-inositoloocyte qualityinsulin resistanceintegrative medicineclinical trial design

Zitieren

APA

Bizzarri, M., & Monti, N. (2019). Reproducibility crisis. Impact on uncontrolled release of nutraceutical preparations. Organisms. Journal of Biological Sciences, 3(1), 9-10. https://doi.org/10.13133/2532-5876_5.2

Vancouver

Bizzarri M, Monti N. Reproducibility crisis. Impact on uncontrolled release of nutraceutical preparations. Organisms. Journal of Biological Sciences. 2019;3(1):9-10. doi:10.13133/2532-5876_5.2

BibTeX
@article{Bizzarri2019,
  author = {Bizzarri, Mariano and Monti, Noemi},
  title = {Reproducibility crisis. Impact on uncontrolled release of nutraceutical preparations},
  journal = {Organisms. Journal of Biological Sciences},
  year = {2019},
  volume = {3},
  number = {1},
  pages = {9--10},
  doi = {10.13133/2532-5876_5.2}
}
Kostenlos starten →